Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major

Vox Sanguinis

Volumn 79, Issue 3, 2000, Pages 129-137

  Prati, Daniele ^a,b  

^a MAGGIORE HOSPITAL   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IRON;

ANEMIA; BETA THALASSEMIA; BLOOD TRANSFUSION; CHRONIC HEPATITIS; HEART DISEASE; HEPATITIS C; HUMAN; INFECTION RISK; IRON CHELATION; IRON OVERLOAD; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; THALASSEMIA MAJOR;

EID: 0033672897     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1159/000031230     Document Type: Review

References (78)

1. The thalassemias
2. The beta-thalassemias
3. Transfusion requirements and effects in patients with thalassaemia major
4. Blood transfusion in beta thalassemia major
5. Iron-chelating therapy and the treatment of thalassemia
6. The current risk of retroviral infections transmitted by transfusion in patients who have undergone multiple transfusions
7. A multicenter prospective study on the risk of acquiring liver disease in anti-HCV negative patients affected from homozygous β-thalassemia
8. Survival and causes of death in thalassaemia major
9. Survival and disease complications in thalassemia major
10. Hypersplenism and hyposplenism
11. Leukocyte depletion of red cells
12. Iron and chronic viral hepatitis
13. Leukocyte-reduced blood products
14. Clinical data on SENV
15. Evidence for and against additional hepatitis agents
16. The molecular identification of potential new pathogens: Some considerations
17. The incidence and natural course of transfusion-associated GB virus C/hepatitis G virus infection in a cohort of thalassemic patients
18. A prospective study on TT virus (TTV) infection in transfusion-dependent patients with β-thalassemia
19. Antibody to hepatitis C virus in 1,305 Italian multiply transfused thalassae-mics: Comparison of first and second generation tests
20. HIV and HTLV infections in 1305 transfusion-dependent thalassemics in Italy
21. Thalassemia intermedia
22. Risultati a lungo termine della terapia del morbo di Cooley
23. Transfusion therapy in Cooley's anemia: Growth and health as related to long-range hemoglobin levels: A progress report
24. Hypertransfusion regimen in patients with Cooley's anemia
25. New approaches to the transfusion management of thalassemia
26. A home transfusion programme for beta-thalassemia patients
27. Splenectomy in childhood: The laparoscopic approach
28. Comparison of a transfusion preparation of newly formed red cells and standard washed red cell transfusions in patients with homozygous beta-thalassemia
29. A study on the value of red cell exchange transfusion in transfusion dependent anemias
30. Successful use of hydroxyurea in a patient with β-thalassemia major
31. Elimination of transfusions through induction of fetal hemoglobin synthesis in Cooley's anemia
32. Hemoglobin switching protocols in thalassemia: Experience with sodium phenylbutyrate and hydroxyurea
33. Red cell alloantibodies in thalassemia major: Results of an Italian cooperative study
34. Severe reactions associated with transfusion of patients with sickle cell disease
35. High-dose intravenous immunoglobulin in the management of autoimmune hemolytic anemia complicating thalassemia major
36. Alloimmunization to red cell antigens in thalassemia: Comparative study of usual versus better-match transfusion programmes
37. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions
38. Iron-chelation therapy with oral deferiprone: Toxicity or lack of efficacy?
39. Survival of medically treated patients with homozygous β-thalassemia
40. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major
41. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major
42. Noninvasive methods for the early detection of hereditary hemochromatosis
43. Association of heart failure in homozygous beta-thalassemia with the major histocompatibility complex
44. Apolipoprotein E ε4 allele as a genetic risk factor for left ventricular failure in homozygous β-thalassemia
45. Myocarditis in beta-thalassemia major: A cause of heart failure
46. Transfusion-transmitted human parvovirus B19 infection in a thalassemic patient
47. Thromboembolic events in beta thalassemia major: An Italian multicenter study
48. Thrombotic risk in thalassemic patients
49. A chronic hypercoagulable state in patients with beta-thalassemia major is present in childhood
50. Diabetes mellitus and chronic hepatitis C virus infection
51. HTLV-III neutralizing antibody development in transfusion-dependent seropositive patients with beta-thalassemia
52. Antibodies to HTLV-III and the lymphadenopathy syndrome in multitransfused beta-thalassemia patients
53. The risk of transfusion-transmitted viral infections
54. Liver histological findings in adult thalassemia major patients under regular chelation therapy with desferrioxamine
55. Prevalence and clinical features of cryoglobulinaemia in multitransfused beta-thalassaemia patients
56. The incidence and risk factors of community-acquired hepatitis C in a cohort of Italian blood donors
57. Cirrhosis associated with multiple transfusions in thalassaemia
58. Chronic liver disease in transfusion-dependent thalassemia: Liver iron quantitation and distribution
59. Iron state and hepatic disease in patients with thalassaemia major, treated with long-term subcutaneous deferoxamine
60. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
61. Long-term efficacy of α-interferon in β-thalassemics with chronic hepatitis C
62. Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissible agent
63. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology
64. High rates of hepatitis G virus infection in multi-transfused patients with hemophilia
65. TT virus is present in a high frequency in Italian hemophilic patients transfused with plasma-derived clotting factor concentrates
66. Nonbacterial pneumonia after allogeneic marrow transplantation: A review of 10 years' experience
67. Human parvovirus and thalassemia
68. Viral infections in transfusion-dependent patients with beta-thalassemia major: The predominant role of cytomegalovirus
69. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant
70. Infection due to Yersinia enterocolitica in a series of patients with beta-thalassemia: Incidence and predisposing factors
71. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy
72. Oversight and monitoring of blood safety in the United States
73. Cloning the differences between two complex genomes